Supplementary Table S2 from Intratumoral CD16⁺ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Documenti analoghi

• Supplementary Table S1 from Intratumoral CD16⁺ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
  di: Hansol Lee (15054787)
  Pubblicazione: (2025)
• Supplementary Table S3 from Intratumoral CD16⁺ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
  di: Hansol Lee (15054787)
  Pubblicazione: (2025)
• Supplementary Table S4 from Intratumoral CD16⁺ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
  di: Hansol Lee (15054787)
  Pubblicazione: (2025)
• Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
  di: Renumathy Dhanasekaran (14962092)
  Pubblicazione: (2025)
• Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4⁺ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
  di: Hiroshi Kagamu (14961732)
  Pubblicazione: (2025)